Values First Advisors Inc. Sells 7,027 Shares of Mirum Pharmaceuticals, Inc. $MIRM

Values First Advisors Inc. reduced its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 42.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,397 shares of the company’s stock after selling 7,027 shares during the period. Values First Advisors Inc.’s holdings in Mirum Pharmaceuticals were worth $868,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of MIRM. Cullen Frost Bankers Inc. purchased a new stake in Mirum Pharmaceuticals in the fourth quarter worth about $30,000. Eurizon Capital SGR S.p.A. purchased a new position in shares of Mirum Pharmaceuticals during the fourth quarter valued at approximately $32,000. CIBC Private Wealth Group LLC bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $32,000. Quantbot Technologies LP bought a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter worth approximately $33,000. Finally, Comerica Bank grew its stake in shares of Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after buying an additional 278 shares during the last quarter.

Insider Transactions at Mirum Pharmaceuticals

In related news, SVP Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $101.95, for a total value of $264,458.30. Following the completion of the sale, the senior vice president directly owned 5,835 shares in the company, valued at approximately $594,878.25. This trade represents a 30.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $95.84, for a total value of $2,875,200.00. Following the completion of the transaction, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at approximately $18,622,574.56. This trade represents a 13.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 37,594 shares of company stock worth $3,608,758 over the last quarter. 8.32% of the stock is currently owned by insiders.

Analyst Ratings Changes

MIRM has been the subject of a number of recent research reports. Stifel Nicolaus set a $136.00 price objective on Mirum Pharmaceuticals in a research note on Thursday, May 7th. HC Wainwright restated a “buy” rating on shares of Mirum Pharmaceuticals in a report on Monday, June 15th. Citizens Jmp raised their price target on Mirum Pharmaceuticals from $140.00 to $146.00 and gave the company a “market outperform” rating in a report on Monday, June 15th. Wolfe Research began coverage on Mirum Pharmaceuticals in a research report on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 price target for the company. Finally, Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $139.80.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM opened at $107.77 on Tuesday. The firm has a market cap of $6.57 billion, a P/E ratio of -7.92 and a beta of 0.50. Mirum Pharmaceuticals, Inc. has a twelve month low of $47.89 and a twelve month high of $114.99. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28. The company has a 50 day moving average of $98.87 and a 200 day moving average of $92.64.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, May 6th. The company reported ($13.43) EPS for the quarter, missing the consensus estimate of ($0.75) by ($12.68). The business had revenue of $159.88 million for the quarter, compared to analysts’ expectations of $148.21 million. Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The business’s revenue for the quarter was up 43.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.30) earnings per share. As a group, research analysts expect that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.